Gentian Diagnostics AS

GENT · Oslo Børs · Healthcare

39.00NOK 0.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −27.1%

Performance

1 month

−0.3%

1 year

−27.1%

3 years, per year

−0.9%

5 years, per year

−12.8%

Largest fall, 3 years

−58.4%

Below the peak now

−53.7%

Volatility, 1 year

52.7%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

3.4

Dividend yield

1.5%

Return on equity

−4.6%

Net margin

−4.6%

Market value

63 m USD

Quality, value and trend

Where Gentian Diagnostics stands against every Nordic stock today. 100 is best.

Quality63

Profitability and a sound balance sheet over time. Better than 63% of Nordic stocks.

Value22

The price measured against earnings, assets and cash flow. Better than 22% of Nordic stocks.

Trend50

The price development over the past year. Better than 50% of Nordic stocks.

Combined38

Quality, value and trend together. Better than 38% of Nordic stocks.

About Gentian Diagnostics

Gentian Diagnostics AS is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 63 employees.

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis